Focal hyperhidrosis: diagnosis and management

Aamir Haider, Nowell Solish

Abstract

HYPERHIDROSIS, A CONDITION CHARACTERIZED by excessive sweating, can be generalized or focal. Generalized hyperhidrosis involves the entire body and is usually part of an underlying condition, most often an infectious, endocrine or neurologic disorder. Focal hyperhidrosis is idiopathic, occurring in otherwise healthy people. It affects 1 or more body areas, most often the palms, armpits, soles or face. Almost 3% of the general population, largely people aged between 25 and 64 years, experience hyperhidrosis. The condition carries a substantial psychological and social burden, since it interferes with daily activities. However, patients rarely seek a physician’s help because many are unaware that they have a treatable medical disorder. Early detection and management of hyperhidrosis can significantly improve a patient’s quality of life. There are various topical, systemic, surgical and nonsurgical treatments available with efficacy rates greater than 90%–95%.

CMAJ 2005;172(1):69-75
DOI:10.1503/cmaj.1040708

Hyperhidrosis, or increased production of sweat, can have a deeply detrimental effect on a patient’s quality of life, resulting in dramatic impairments of daily activities, social interactions and occupational activities. It can be generalized, involving the whole body, or focal, involving a limited body area, most often the feet, armpits, hands or face. It is as common a disorder as psoriasis. However, patients rarely seek a physician’s help because many are unaware that they have a treatable medical disorder. In this article, we review the possible causes, pathophysiology, diagnosis and clinical manifestations of focal hyperhidrosis as well as the wide range of treatment modalities available today.

Epidemiology

A recent large epidemiological survey of 150 000 households in the United States has revealed that focal hyperhidrosis is present in 2.8% of the general population. The condition affects both men and women equally, and its prevalence was found to be the highest among people aged 25–64 years. The average age of onset is 25 but depends primarily on the body area affected. Palmar and axillary hyperhidrosis have the earliest average onset, at 13 and 19 years respectively. As many as 82% of patients with palmar hyperhidrosis have reported onset in childhood. Focal hyperhidrosis appears to have an onset in childhood; however, people may not seek medical help until early adulthood. Armpits are affected in 51% of patients, feet in 29%, palms in 25% and the face in 20%.

Pathophysiology

The pathophysiology of focal hyperhidrosis is poorly understood. Sweat is produced by the body’s sweat glands: there are up to 4 million sweat glands, of which about 3 million are eccrine sweat glands and the remainder are apocrine glands. Eccrine sweat glands are innervated by cholinergic fibres from the sympathetic nervous system. Their primary function is the secretion of sweat — an odourless, clear fluid that regulates body temperature — the rate of which is affected by emotional and gustatory stimuli. Eccrine sweat glands, which are responsible for focal hyperhidrosis, are distributed over nearly the entire body surface, although their density is highest in the soles of the feet and the forehead, followed by the palms and cheeks. Apocrine sweat glands are scent glands and are primarily confined to the axillary and urogenital regions. They are not involved in focal hyperhidrosis, and their function is regulated by hormonal processes. There are also mixed sweat glands called apoeccrine glands, which are primarily found in axillary and perianal areas. Their role in the pathophysiology of focal hyperhidrosis is unknown, although in some patients they constitute up to 45% of the sweat glands found in the axillary region.

No histopathological changes in the sweat glands have been observed in patients with focal hyperhidrosis, nor do these patients have increased numbers of or larger sweat glands. Rather, focal hyperhidrosis may represent a complex dysfunction of the autonomic nervous system, involving both the sympathetic and parasympathetic pathways. A genetic predisposition may exist, since 30%–50% of patients have a family history of hyperhidrosis. In a study by Shih and colleagues, patients with palmar and axillary hyperhidrosis showed less reflex bradycardia in response to Valsalva’s manoeuvre and a higher degree of vasoconstric-
tion in response to finger immersion in cold water. Such an increased sympathetic activity through the T2–T3 ganglia could cause palmar hyperhidrosis. Excessive palmar and plantar sweating could thus result in a vicious cycle, as evaporative cooling of the skin increases sympathetic outflow through reflex action, which in turn increases sweat output. Parasympathetic dysfunction was implicated in a study that compared heart rate variability in patients with focal hyperhidrosis with that of healthy control subjects. The authors found that, although sympathetic activity seemed to be similar, patients with focal hyperhidrosis exhibited heart rate patterns suggesting parasympathetic dysfunction.

**Diagnosis and clinical presentation**

The first step in the evaluation of hyperhidrosis is to differentiate between generalized and focal hyperhidrosis. Generalized hyperhidrosis is usually part of some other underlying condition, such as infective or malignant disease or a hormonal disorder, and focal or primary idiopathic hyperhidrosis occurs in otherwise healthy people (Box 1). It usually peaks in the second or third decade of life and manifests as bilateral excessive sweat production confined to the armpits, soles of the feet, palms of the hands, face or other specific sites. Gustatory sweating (Frey’s syndrome) is also a form of focal hyperhidrosis. A positive family history is evident in 30%–50% of patients. Furthermore, patients with focal hyperhidrosis generally do not sweat during sleep. Thus, a medical history focusing on location of excessive sweating, duration of the presentation, family history, age at onset and the absence of any apparent cause allows one to easily differentiate focal from generalized hyperhidrosis (Box 2).

Although there is no standard definition of focal hyperhidrosis, less than 1 mL/m² of sweat production per minute by eccrine glands at rest and at room temperature is considered normal. Alternatively, sweat rates of discrete anatomic areas (e.g., palm, axilla) may be measured for research purposes (e.g., normal sweat rates for the axilla are < 20 mg/min). For practical clinical purposes, any degree of sweating that interferes with the activities of daily living should be viewed as abnormal.

```plaintext
Box 1: Causes of generalized and focal hyperhidrosis

**Focal hyperhidrosis**
- Primary idiopathic hyperhidrosis
- Gustatory sweating (Frey’s syndrome)

**Neurologic**
- Neuropathies
- Spinal injury

**Generalized hyperhidrosis**
- Endocrine
  - Hyperthyroidism
  - Hyperpituitarism
  - Diabetes mellitus
- Menopause
- Pregnancy
- Pheochromocytoma
- Carcinoid syndrome
- Acromegaly

**Neurologic**
- Parkinson’s disease
- Spinal cord injury
- Cerebrovascular accident
- Malignant disease
  - Myeloproliferative disorders
  - Hodgkin’s disease

**Box 2: Diagnostic criteria for primary focal idiopathic hyperhidrosis**

Focal, visible, excessive sweating of at least 6 mo duration without apparent cause with at least 2 of the following characteristics:
- Bilateral and relatively symmetric sweating
- Frequency of at least 1 episode per wk
- Impairment of daily activities
- Age at onset < 25 yr
- Positive family history
- Cessation of sweating during sleep
```

Psychosocial impairment is a significant aspect of focal hyperhidrosis (Box 3). In a US survey, one-third of patients with axillary hyperhidrosis reported their sweating as being barely tolerable or intolerable and as frequently interfering with activities of daily living; 35% of patients reported a decrease in leisure activity time due to excessive...
sive sweating. Many patients with focal hyperhidrosis go to considerable lengths to hide their condition, and social interactions are significantly impaired, since patients experience feelings of humiliation and embarrassment. Simple aspects of socialization, such as shaking hands or hugging, become awkward. Focal hyperhidrosis also has a profound impact on occupational activities. Despite this, only one-third of the survey participants had consulted a physician about their problem. Clearly, primary care physicians can be instrumental in the initial diagnosis and assessment of this condition.

**Treatment**

There is a wide range of nonsurgical (e.g., topical, systemic) and surgical treatments available for patients with focal hyperhidrosis. These treatment modalities vary in their therapeutic efficacy, duration of effect, side effects and cost, as well as in the scientific evidence of their efficacy (Table 1 and Table 2).

**Topical treatments**

Aluminum salts are the most common ingredient in over-the-counter antiperspirants used to treat focal hyperhidrosis. It has been postulated that the mechanism of their action is related to mechanical obstruction of the eccrine gland duct or to atrophy of the secretory cells. The concentrations of aluminum salts in most commercial antiperspirants is 1%–2%; however, aluminum chloride solutions are available in 20%–25% concentrations. Repeated applications are often necessary every 24–48 hours. Improvement can be seen in mild cases within 3 weeks of treatment. The major limitation of aluminum chloride products is localized burning, stinging and irritation. To minimize irritation, these products can be applied to the affected area at bedtime and washed off after 6–8 hours. According to the literature, 25% aluminum chloride is an effective first-line treatment for mild axillary hyperhidrosis. Aluminum chloride 20% can reduce palmar hyperhidrosis within 48 hours after application, but the effect diminishes within 48 hours after the end of treatment. Aluminum chloride 20% in alcohol can be effective in as many as 98% of cases of mild axillary hyperhidrosis.

Topical aldehyde agents, such as formaldehyde and glutaraldehyde, have limited use in the treatment of focal hyperhidrosis because they can cause allergic sensitization and localized skin irritation.

**Iontophoresis**

Iontophoresis is defined as the introduction of ions into the skin by means of an electrical current. The mode of action is not yet clear, but it is postulated that a charged particle obstructs the duct or the electrical change disrupts

---

**Box 3: Burden of disease in hyperhidrosis**

- Severe embarrassment associated with soaked clothing and wet palms
- Change of clothing required 2 or more times per day
- Handshaking avoided when possible
- Frustration with activities of daily living
- Impairment of performance and productivity at work
- Change in the type of leisure activities pursued
- Missed social gatherings with friends and family
- Depression and lack of confidence
- Skin maceration from constant wetness can lead to bacterial and fungal infections
- Difficulty with social and intimate relationships
eccrine gland secretion. The procedure entails placing the hands or feet in a shallow basin filled with water, through which an electric current is passed. Iontophoresis is primarily used for focal palmoplantar hyperhidrosis, since the hands and feet are the easiest body parts to submerge in water.

Iontophoresis has not been studied in large randomized controlled trials, but it has been reported to be 80%–100% effective in uncontrolled trials. However, long-term maintenance therapy is generally required. The limitation of this treatment is that it causes skin irritation, dryness and peeling. It is also time consuming, as it may require 30–40 minutes per treatment site daily for at least 4 days a week. Normal sweating is generally achieved after 6–10 treatments. Overall, iontophoresis is considered a second-line treatment for focal palmoplantar hyperhidrosis and is contraindicated in patients who are pregnant or who have a pacemaker.

### Table 1: Evidence for medical treatments of focal hyperhidrosis

| Trial | No. of patients | Study design | Intervention; affected area | Outcome measure | Result | p value | Follow-up period | Comment |
|-------|-----------------|--------------|-----------------------------|----------------|--------|---------|-----------------|---------|
| Goh et al | 12 | Controlled, single blind; within patient comparison | Aluminum chloride 20%; palms | Rate of skin vapour loss (g/m² per hour) | Treated: 51.4 g/m² (SD 16.5) Control: 72.7 g/m² (SD 17.0) | 0.004 | NA | Skin irritation in 4/12 (33%) |
| Scholes et al | 65 | Prospective, uncontrolled | Aluminum chloride 20%; axillae | Self-reported improvement | 64/65 (98%) reported excellent control of sweating | NA | 12 mo | Skin irritation in 29/65 (45%) |
| Karakoc et al | 112 | Prospective, uncontrolled | Iontophoresis; palms, soles | No recurrence of symptoms 20 d after end of treatment | 91/112 (81%) | NA | 20 d | Vesicles 8/112 (7%); Erythema 10/112 (9%); Discomfort 16/112 (14%) |
| Reinauer et al | 25 | Controlled, single blind | Iontophoresis (comparison of DC, AC, and AC with DC offset); palms, soles | Gravimetric sweat rate (mg/min) | No change with AC alone; both DC and AC with DC offset resulted in normal sweat rates (&lt; 20 mg/min) after 11 sessions | NA | 3 wk | Acrocyanosis, edema (rates not provided) |
| Holze et al | 71 | Prospective, uncontrolled | Iontophoresis; palms, soles | Gravimetric sweat rate (mg/min) | Palmar: mean 52 mg/min at baseline to &lt; 20 mg/min Plantar: mean 43 mg/min at baseline to &lt; 15 mg/min | NA | 14 mo | Burning, tingling, erythema, vesicles in short term; none in long term |
| Heckmann et al | 145 | Randomized, double blind; within patient comparison of intervention v. placebo | Botulinum toxin; axillae | Gravimetric sweat rate (mg/min) | Treatment: 24 ± 7 mg/min Placebo: 144 ± 113 mg/min Mean difference: 111 mg/min; 95% CI 91–132 mg/min | &lt; 0.001 | 24 wk | Compensatory hyperhidrosis (&lt; 1%); Axillary itching (&lt; 1%); Shoulder muscle soreness (&lt; 1%) |
| Naumann et al | 320 | Randomized, double blind, placebo controlled | Botulinum toxin; axillae | ≥ 50% reduction in gravimetric sweat rate (mg/5 min) | Treatment: 198/320 (82%) Placebo: 167/78 (21%) | &lt; 0.001 | 16 wk | Compensatory hyperhidrosis (5%) |
| Lowe et al | 17 | Randomized double blind; within patient comparison of intervention v. placebo | Botulinum toxin; palms | Patient satisfaction | Treatment: 17/17 (100%) Placebo: 2/17 (12%) | &lt; 0.001 | 4 wk | Transient intrinsic muscle weakness (&lt; 1%) |
| Schnider et al | 11 | Randomized, double blind; within patient comparison of intervention v. placebo | Botulinum toxin; palms | Mean reduction in sweating measured by triketohydrindene hydrate sweat test | Treatment: 31% (95% CI 20%–42%) Placebo: 0.2%–1.2% | &lt; 0.001 | 13 wk | Transient intrinsic muscle weakness (&lt; 1%) |

Note: SD = standard deviation, NA = not available, DC = direct current, AC = alternating current, CI = confidence interval.
**Botulinum toxin A**

Botulinum toxin A is the best-studied treatment to date for focal hyperhidrosis. It is a neurotoxin produced by the anaerobic bacterium *Clostridium botulinum; 7* serotypes of toxin exist, of which type A is the most potent. When used to treat focal hyperhidrosis, botulinum toxin is injected intradermally and acts to inhibit the release of acetylcholine at the neuromuscular junction and from sympathetic nerves that innervate eccrine sweat glands, which results in loss of sweating (Fig. 2 and Fig. 3).14

Botulinum toxin has been evaluated as a treatment for axillary hyperhidrosis in 2 large randomized controlled trials.19,20 A significant improvement was reached in 95% of patients at 1 week, and the average duration of effect was 7 months. For palmar hyperhidrosis, the response rate was greater than 90%;21,22 the duration of effect was generally 4–6 months. The major limitation of this treatment is that the injections are painful and require a nerve block for anesthesia. However, patient satisfaction in randomized controlled trials with botulinum toxin was nearly 100%. Excellent response rates to botulinum toxin injection in plantar hyperhidrosis have also been reported15–17 but still need to be confirmed by controlled studies.

Contraindications to botulinum toxin therapy include neuromuscular disorders such as myasthenia gravis, pregnancy and lactation, organic causes of hyperhidrosis, and medications that may interfere with neuromuscular transmission. For this treatment, patients should be referred to physicians specialized in the administration of botulinum toxin. It must be noted, however, that the cost of the drug is a limitation to its wider use.

**Surgical treatments**

Surgical treatments include endoscopic thoracic sympathectomy, which destroys the sympathetic ganglia by excision, clamping, transection or ablation with cautery or laser. Several retrospective studies and uncontrolled clinical trials have demonstrated that endoscopic thoracic sympathectomy is effective in eliminating axillary, palmar and facial hyperhidrosis in 68%–100% of cases.21–23 Plantar hyperhidrosis was reduced in 58%–85% of patients. The main limitation of this procedure is a high incidence of mild to severe compensatory hyperhidrosis, usually involving the trunk and lower limbs, in up to 86% of patients.24 Other adverse effects include gustatory sweating, phantom sweating (the sensation of impending hyperhidrosis in the absence of sweating), neuralgia, Horner’s syndrome and the risk of hemothorax or pneumothorax.24 Furthermore, lumbar sympathectomy for plantar hyperhidrosis is associated with sexual dysfunction.25 Other surgical procedures with reported efficacy include excision of axillary tissue and subcutaneous axillary curttage and liposuction.26,19 Surgical options for focal hyperhidrosis are associated with high efficacy rates, but they should be reserved for patients for whom other treatments have been ineffective and who appreciate the risks associated with the procedure and potential complications.

| Trial | No. of patients | Study design | Intervention; affected area | Outcome measure | Result | p value | Follow-up period | Side effects |
|-------|----------------|--------------|-----------------------------|----------------|--------|---------|-----------------|-------------|
| Doolabh et al22 | 180 | Retrospective | Endoscopic sympathectomy (cauterization); axillae, palms, soles, face | Self-reported improvement | Satisfied patients: axillae 54/55 (99%); palms 140/140 (100%); soles 72/125 (58%); face 37/39 (95%) | NA | 17 mo | Compensatory hyperhidrosis (78%); Horner’s syndrome (1%); Pneumothorax (2%) |
| Reisfeld et al24 | 1312 | Retrospective | Endoscopic sympathectomy clamping v. cauterization; palms, face | Self-reported improvement | Satisfied patients: clamping 98%; cauterization 95% | < 0.025 | 23 mo | Compensatory hyperhidrosis (> 90%); Pneumothorax (< 1%) |
| Lin et al3 | 1360 | Retrospective | Endoscopic sympathectomy (cauterization); palms | Self-reported improvement | Resolution of symptoms in 99% of patients immediately and at follow-up | NA | 28 mo | Compensatory hyperhidrosis (84%); Pneumothorax (< 1%) |
| Zacherl et al25 | 369 | Retrospective | Endoscopic sympathectomy with v. without video assistance (cauterization); axillae, palms | Self-reported improvement | With video assistance 27/30 (90%) had dry limbs; without video assistance 239/293 (91%) had dry limbs | NA | 36 mo | Compensatory hyperhidrosis (69%); Horner’s syndrome (2%) |
| Proebstle et al26 | 38 | Prospective, uncontrolled before-after comparison | Subcorial curettage; axillae | Gravimetric sweat rate (mg/min) | Mean sweat rate before curettage 48.4 mg/min; after curettage 18.1 mg/min | < 0.001 | 8 wk | Scars (53%); Paresthesia (33%); Pigmentation (33%); Partial alopecia (44%) |
**Systemic treatments**

The main systemic agents used to treat focal hyperhidrosis are anticholinergic agents. By inhibiting synaptic acetylcholine, they interfere with neuroglandular signalling. The main limitation of these drugs is that the doses required to achieve reduced sweating may also result in adverse effects such as dry mouth, blurred vision, urinary retention, constipation and tachycardia. Glycopyrrolate, an anticholinergic drug, at initial doses of 1 mg twice daily may improve hyperhidrosis, but the eventual dosage required usually results in unacceptable side effects. Other systemic agents include amitriptyline, clonazepam, β-blockers (e.g., propranolol) and calcium-channel blockers (e.g., diltiazem), gabapentin and indomethacin. However, these drugs have been used mostly by patients with generalized hyperhidrosis; their role in the treatment of focal hyperhidrosis remains to be established.

**Alternative treatments**

Biofeedback training, hypnosis and different types of relaxation techniques have been used to treat hyperhidrosis, but research data on their efficacy are still scarce to nonexistent. The lack of well-designed trials and long-term follow-up limits their use.

**Conclusion**

Various treatments of focal hyperhidrosis are available. Aluminum chloride-based topical treatments can be used as first-line treatment of axillary hyperhidrosis, which is the most frequent form of focal hyperhidrosis, as well as of palmar hyperhidrosis. Iontophoresis can be used as second-line treatment of palmar and plantar hyperhidrosis. Botulinum toxin seems the most effective treatment, but it is painful and costly. Surgical thoracic sympathectomy may be the only solution for patients with severe hyperhidrosis in whom other treatments have not produced satisfactory results. The role of alternative and systemic treatments in focal hyperhidrosis remains to be established. Given that effective treatment can result in dramatic improvements to a patient’s quality of life, physicians can play an instrumental role in the diagnosis and management of this distressing condition.

---

Fig. 2: Intradermal botulinum toxin injections for the treatment of axillary hyperhidrosis. Focal axillary hyperhidrosis is treated with 50–200 units of botulinum toxin A per axilla. The usual starting dose is 50 units per axilla. The drug is injected intradermally using a 13-mm-long 30-gauge needle. Injections are done in a grid-like pattern in order to cover the entire affected area, with injection sites generally 1–2 cm apart. There is no difference in efficacy of botulinum toxin A in the treatment of axillary hyperhidrosis when administered by subcutaneous or intradermal injection, but intradermal injections are reported to be more painful. The subcutaneous injection technique requires further study for validation of the results.

Fig. 3: Intradermal botulinum toxin injections for the treatment of palmar hyperhidrosis. For palmar hyperhidrosis, intradermal injections spaced about 1–2 cm apart seem to give the best results. About 2 units of botulinum toxin A are injected per site as required, with a total dose of 100 units for each palm. The main limitation is that most patients find the injections painful and may require regional anesthesia via median, ulnar and radial nerve blocks at the wrist level. A similar technique and dosage of botulinum toxin A is used for the treatment of plantar hyperhidrosis, requiring regional nerve blocks of posterior tibial and sural nerves for anesthesia. Other methods of reducing the pain of injections have included high-intensity vibration devices, cool packs and liquid nitrogen spray, all with variable results.
References

1. Amir M, Arish A, Weinstein Y, Pfeffer M, Levy Y. Impairment in quality of life among patients seeking surgery for hyperhidrosis (excessive sweating): preliminary results. *Int J Psychiatry Relat Sci* 2000;37(1):25-31.

2. Lerer B, Jacobowitz J, Wahaba A. Personality features in essential hyperhidrosis. *Int J Psychiatry Med* 1981;10:59-67.

3. Christophers E, Kruger G. Psoriasis. In: Fitzpatrick TB, Eisen AZ, Wolff K, editors. *Dermatology in general medicine*. 3rd ed. New York: McGraw-Hill; 1987. p. 465.

4. Strueber DR, Kowalski JW, Glaser DA, Stang PE. US prevalence of hyperhidrosis and impact on individuals with axillary hyperhidrosis: Results from a national survey. *J Am Acad Dermatol* 2004;51(2):241-8.

5. Lin TS, Fang HY. Transthoracic endoscopic sympathectomy in the treatment of palmar hyperhidrosis — with emphasis on perioperative management (1360 case analysis). *Surg Neurol* 1999;52:453-7.

6. Kinkelin I, Hund M, Naumann M, Hamm H. Effective treatment of frontal hyperhidrosis with botulinum toxin A. *Br J Dermatol* 2000;143(4):824-7.

7. Sato K, Kang WH, Saga K, Sato KT. Biology of sweat glands and their disorders II. Disorders of sweat gland function. *J Am Acad Dermatol* 1989;20(Pt 1):713-26.

8. Sato K, Kang WH, Saga KT. Biology of sweat glands and their disorders I. Normal sweat gland function. *J Am Acad Dermatol* 1989;20(Pt 1):337-63.

9. Stolman LP. Treatment of hyperhidrosis. *Dermatol Clin* 1998;16:863-7.

10. Shih CJ, Wu JJ, Lin MT. Autonomic dysfunction in palmar hyperhidrosis. *J Auton Nerv Syst* 1993;48:83-83.

11. Birner P, Heinzl H, Schindl M, Pumprla J, Schnider P. Cardiac autonomic hyperhidrosis and impact on individuals with axillary hyperhidrosis: Results from a national survey. *J Am Acad Dermatol* 2004;51(2):241-8.

12. Lin SF. Transthoracic endoscopic sympathectomy in the treatment of palmar hyperhidrosis — with emphasis on perioperative management (1360 case analysis). *Surg Neurol* 1999;52:453-7.

13. Reinauer S, Neusser A, Schauf G, Holzle E. Iontophoresis with alternating current and direct current offset (AC/DC iontophoresis): a new approach for the treatment of hyperhidrosis. *Ann Rev Pharmacol Toxicol* 1999;39:223-36.

14. Goh CL. Aluminum chloride hexahydrate versus palmar hyperhidrosis, evaporation therapy. *Int J Dermatol* 1999;38:568-70.

15. Schole KT, Crow KD, Ellis JP, Harman RK, Saitam EH. Axillary hyperhidrosis treated with alcoholic solution of aluminum chloride hexahydrate. *BMJ* 1978;2:84-5.

16. Karakoc Y, Aydemir EH, Kalkan MT, Unal G, et al. Safe control of palmpalan- tar hyperhidrosis with direct electrical current. *Int J Dermatol* 2002;41(9):602-5.

17. Reinauer S, Neusser A, Schauf G, Holzle E. Iontophoresis with alternating current and direct current offset (AC/DC iontophoresis): a new approach for the treatment of hyperhidrosis. *Br J Dermatol* 1993;129(2):166-9.

18. Holze L, Alberti N. Long term efficacy and side effects of tap water iontophoresis of palmpalan- tar hyperhidrosis — the usefulness of home treatment. *Dermatologica* 1987;175:126-35.

19. Heckmann M, Ceballos-Baumann AO, Plevig G. Botulinum toxin A for axil- lary hyperhidrosis. *N Engl J Med* 2001;344:488-93.

20. Naumann M, Lowe NJ. Botulinum toxin type A in treatment of bilateral primary axillary hyperhidrosis: a randomised, parallel group, double blind, placebo controlled trial. *BMJ* 2001;323:596-9.

21. Lowe NJ, Yamashita PS, Lask GP, Pannik R, Iyer S. Efficacy and safety of botulinum toxin type A in the treatment of palmar hyperhidrosis: A double blind randomized placebo controlled study. *Dermatol Surg* 2002;28(9):822-7.

22. Schneider P, Binder M, Auf E, Kintler H, Berger T, Wolf K. Double blind trial of botulinum A toxin for the treatment of focal hyperhidrosis of the palms. *Br J Dermatol* 1997;136(4):548-52.

23. Doolabh N, Horswell S, Williams M, Huber L, Prince S, Meyer DM, et al. Thoracoscopic sympathectomy for hyperhidrosis: indications and results. *Ann Thorac Surg* 2004;77(2):410-4.

24. Reisfeld R, Nguyen R, Przni A. Endoscopic thoracic sympathectomy for hyperhidrosis. *Surg Laparosc Endosc Percutan Tech* 2002;12(4):255-67.

25. Zacherl J, Imhof M, Huber ER, Pfas EG, Herbst F, Jakes R, Video assistance reduces complication rate of thoracoscopic sympathectomy for hyperhidrosis. *Ann Thorac Surg* 1999;68(4):1177-81.

26. Ploeseltl TM, Schindler V, Klop J. Gravimetrically controlled efficacy of subcutaneous resection: a prospective study for treatment of axillary hyperhidro- sis. *Dermatol Surg* 2002;28(11):1022-6.

27. Holze E, Klingman AM. Mechanism of antiperspirant action of aluminum salts. *J Soc Cosm Chem* 1979;30:279-95.

28. Shelly W, Hurley HJ. Studies on topical antiperspirant control of axillary hyperhidrosis. *Acta Derm Venereol (Stockh)* 1975;55:241-60.

29. White JW. Treatment of primary hyperhidrosis. *Mayo Clin Proc* 1986;61:951-6.

30. Sato K, Timme DE, Sato F, Templeton EA, Meletiou DS, Toyonoto T, et al. Generation and transit pathway of H+ is critical for inhibition of palmar sweating by iontophoresis in water. *J Appl Physiol* 1993;75(3):2238-64.

31. Bouman H. Treatment of hyperhidrosis of hands and feet with constant current. *Am J Phys Med 1972;31:158-69.

32. Simpson LL. Molecular pharmacology of botulinum toxin and tetanus toxin. *Ann Rev Pharmacol Toxicol* 1986;26:427-53.

33. Pearson C, Cliff S. Botulinum toxin type A treatment for axillary hyperhidrosis: a comparison of intradermal and subcutaneous injection techniques. *Br J Dermatol* 2004;151(suppl 68):95.

34. Connolly M, de Berker D. Management of primary hyperhidrosis. *Am J Clin Dermatol* 2003;4(10):681-97.

35. Naumann M. Focal hyperhidrosis: effective treatment with intracutaneous botulinum toxin. *Arch Dermatol* 1998;134(3):301-4.

36. Sevim S, Dogu O, Kaleagasi H. Botulinum toxin A therapy for palmar and plantar hyperhidrosis. *Acta Neurol Belg* 2002;102(4):167-70.

37. Vodoud-Seyedi J, Simonart T, Heen T. Treatment of plantar hyperhidrosis with dermojet injections of botulinum toxin. *Dermatolology* 2000;201(2):179.

38. Jemec B. Abrazos axillae in hyperhidrosis. *Saud J Plast Reconstr Surg* 1975;9:44-6.

39. Lillis PJ, Coleman WP. Liposuction for the treatment of axillary hyperhidro- sis. *Dermatol Clin* 1990;8:479-82.

40. Eedy DJ, Corbett Jr. Olfactory facial hyperhidrosis responding to amitriptyline. *Clin Exp Dermatol* 1978;13:298-9.

41. Tkach JR. Indomethacin treatment of generalized hyperhidrosis. *J Am Acad Dermatol* 1982;6:545.

42. Fedor R. Clonidine treatment of excessive sweating. *J Clin Psychiatry* 1995;56:335.

43. Duller P, Gentry WD. Use of biofeedback in treating chronic hyperhidrosis: a preliminary report. *Br J Dermatol* 1980;103:143-6.

44. Shenefeld PD. Hypnosis in dermatology. *Arch Dermatol* 2000;136:393-9.

Correspondence to: Dr. Nowell Solish, Rm. 841, 76 Grenville St., Sunnybrook and Women’s College Health Sciences Centre, Toronto ON M5S 1B2